Skip to content

News
Contact Us
Linkedin

Home
About Us
- Executive Team
Cycloset
T2D Disease State
Pipeline
- Cycloset for Pediatric T2DM Patients
- VS41157 for Pancreatic Cancer
Technologies
Therapeutic Areas
- Metabolic Diseases
- Immunological Disorders
Partners & Collaborators
Publications

Creators of Cycloset^®*, the first and only FDA approved sympatholytic dopamine D2 receptor agonist for the treatment of type 2 diabetes.
*See full prescribing info

Veroscience > News > Archive News

Share
Print

Category: Archive News

American Diabetes Association 78th Scientific Sessions

http://professional.diabetes.org/meeting/scientific-sessions/78th-scientific-sessions

AACE 27th Annual Scientific and Clinical Congress

https://www.aace.com/annualmeeting/aace-2018l

American Diabetes Association 77th Scientific Sessions

http://professional.diabetes.org/meeting/scientific-sessions/77th-scientific-sessions

Pri-Med West Annual Conference

http://www.pri-med.com/medical-conferences/2017/annual-conference-west.aspx

AACE 26th Annual Scientific and Clinical Congress

http://aace2017.org/index.html

Endocrine Society 99th Annual Meeting

https://www.endocrine.org/endo-2017

Endocrine Society 100th Annual Meeting

https://www.endocrine.org/endo-2018

Pri-Med South Annual Conference

https://www.pri-med.com/medical-conferences/2017/annual-conference-south.aspx

AACE Georgia

https://www.aace.com/chapters/georgia

Cardiometabolic Health Congress Regional Conference Series

http://www.cardiometabolichealth.org/2016/regional/chicago.html

Posts pagination

< 1 2 3 4 >

Search for:

Recent Comments

Archives

Categories

No categories

Meta

Log in
Entries feed
Comments feed
WordPress.org

About Us
Executive Team

Cycloset
Cycloset Clinical Profile
Mechanism of Action
Pre-Clinical Studies
Clinical Studies
U.S. Cycloset Patents
www.cycloset.com

Pipeline
Cycloset for Pediatric T2DM Patients
VS41157 for Pancreatic Cancer

Technologies
Circadian Neuroendocrine Resetting Therapy (CNRT)
CNRT Overview Video References
Photo Immuno-Resetting Therapy for the Treatment of Cancer

Therapeutic Areas
Metabolic Diseases
Immunological Disorders

Partners & Collaborators
News
Publications
Contact Us
Site Map
Terms of Use

Website by Axxiem

© Copyright . All Right Reserved

By accessing our website or software provided by our third-party vendors, you consent to accept cookies, (including other identifiers). These include pieces of text that are stored on your computer or device. This site uses cookies and Google Analytics to improve navigation, minimize the need to reenter information previously entered on forms, personalize messages, and collect statistical information to improve site navigation and provide content of greatest interest to users.

Cookie settings ACCEPT

Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT